Results From Clinical Trials of Alexion’s Soliris Published

Patients with a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH) experienced a 92 percent reduction in the incidence of life-threatening blood clots following treatment with Alexion Pharmaceuticals’ Soliris, according to an analysis of clinical studies recently published online in Blood, the journal of the American Society of Hematology.

Soliris (eculizumab) is the first therapy approved for PNH, a rare, life-threatening blood disorder defined by the destruction of red blood cells.

The publication analyzed data from 195 patients studied in the Soliris Phase II and Phase III trials, including the TRIUMPH and SHEPHERD studies.

Patients were enrolled in the U.S., Europe, Australia and Canada and treated with Soliris for up to 54 months. Soliris reduced hemolysis in all treated patients and reduced thrombosis by 92 percent, with three events during Soliris treatment compared with 39 events during the same period of time prior to treatment, according to Alexion.